MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs

European Neuropsychopharmacology

Volumn 19, Issue 5, 2009, Pages 363-370

  Hilli, Johanna ^a,b   Heikkinen, Tuija ^c   Rontu, Riikka ^d,e   Lehtimäki, Terho ^d,e   Kishida, Ikuko ^f   Aklillu, Eleni ^f   Bertilsson, Leif ^f   Vahlberg, Tero ^a   Laine, Kari ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b TYKSLAB   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

COMT; MAO A; Perinatal neonatal adaptation problem; Polymorphism; Serotonergic symptom; SSRI

Indexed keywords

ALPRAZOLAM; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; CITALOPRAM; CYTOCHROME P450; FLUOXETINE; LORAZEPAM; NORADRENALIN; NORFLUOXETINE; PROLACTIN; SEROTONIN;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DNA POLYMORPHISM; DRUG EXPOSURE; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; NEWBORN; PERINATAL PERIOD; PRIORITY JOURNAL; SEROTONIN SYNDROME; SEROTONINERGIC SYSTEM; UMBILICAL CORD BLOOD;

CATECHOL O-METHYLTRANSFERASE; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; METHOXYHYDROXYPHENYLGLYCOL; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PROLACTIN; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC;

EID: 63149182590     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.01.006     Document Type: Article

References (40)

1. Allabi A.C., Gala J.L., Desager J.P., Heusterspreute M., and Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol. 56 (2003) 653-657
2. Arias B., Gasto C., Catalan R., Gutierrez B., Pintor L., and Fananas L. The 5-HT(2A) receptor gene 102T/C polymorphism is associated with suicidal behavior in depressed patients. Am. J. Med. Genet. 105 (2001) 801-804
3. Bertilsson L., Dahl M.L., Dalen P., and Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53 (2002) 111-122
4. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., and Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 386-389
5. Chang M., Dahl M.-L., Tybring G., Götharson E., and Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5 (1995) 358-363
6. Deckert J., Catalano M., Syagailo Y.V., Bosi M., Okladnova O., Di Bella D., Nothen M.M., Maffei P., Franke P., Fritze J., Maier W., Propping P., Beckmann H., Bellodi L., and Lesch K.P. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 8 (1999) 621-624
7. Eisenhofer G., Goldstein D.S., Stull R., Keiser H.R., Sunderland T., Murphy D.L., and Kopin I.J. Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin. Chem. 32 (1986) 2030-2033
8. Hegerl U., Bottlender R., Gallinat J., Kuss H.J., Ackenheil M., and Moller H.J. The serotonin syndrome scale: first results on validity. Eur. Arch. Psychiatry Clin. Neurosci. 248 (1998) 96-103
9. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., and Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66 (1996) 2621-2624
10. Hemeryck A., and Belpaire F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr. Drug Metab. 3 (2002) 13-37
11. Hu X.Z., Lipsky R.H., Zhu G., Akhtar L.A., Taubman J., Greenberg B.D., Xu K., Arnold P.D., Richter M.A., Kennedy J.L., Murphy D.L., and Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am. J. Hum. Genet. 78 (2006) 815-826
12. Illi A., Mattila K.M., Kampman O., Anttila S., Roivas M., Lehtimaki T., and Leinonen E. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. J. Clin. Psychopharmacol. 23 (2003) 429-434
13. In: Ingelman-Sundberg M., Daly A.K., and Nebert D.W. (Eds). Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2007). http://www.cypalleles.ki.se Available at: http://www.cypalleles.ki.se. Accessed May 25
14. Kaiser R., Tremblay P.B., Schmider J., Henneken M., Dettling M., Muller-Oerlinghausen B., Uebelhack R., Roots I., and Brockmoller J. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol. Psychiatry 6 (2001) 179-185
15. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 158 (2004) 312-316
16. Kendler K.S., Kuhn J.W., Vittum J., Prescott C.A., and Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch. Gen. Psychiatry 62 (2005) 529-535
17. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
18. Laine K., Heikkinen T., Ekblad U., and Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60 (2003) 720-726
19. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., and Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 23 (2003) 8788-8799
20. Lesch K.P., Balling U., Gross J., Strauss K., Wolozin B.L., Murphy D.L., and Riederer P. Organization of the human serotonin transporter gene. J. Neural. Transm. Gen. Sect. 95 (1994) 157-162
21. Livak K.J. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet. Anal. 14 (1999) 143-149
22. Mårtensson B., Nyberg S., Toresson G., Brodin E., and Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr. Scand. 79 (1989) 586-596
23. Moses-Kolko E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., and Wisner K.L. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293 (2005) 2372-2383
24. Nakamura M., Ueno S., Sano A., and Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol. Psychiatry 5 (2000) 32-38
25. Neumeister A., Konstantinidis A., Stastny J., Schwarz M.J., Vitouch O., Willeit M., Praschak-Rieder N., Zach J., de Zwaan M., Bondy B., Ackenheil M., and Kasper S. Association between serotonin transporter gene promoter polymorphism (5HTTLPR) and behavioral responses to tryptophan depletion in healthy women with and without family history of depression. Arch. Gen. Psychiatry 59 (2002) 613-620
26. Nordeng H., and Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Safety 28 (2005) 565-581
27. Oberlander T.F., Misri S., Fitzgerald C.E., Kostaras X., Rurak D., and Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry 65 (2004) 230-237
28. Oberlander T.F., Bonaguro R.J., Misri S., Papsdorf M., Ross C.J., and Simpson E.M. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol. Psychiatry 13 (2008) 65-73
29. Ogilvie A.D., Battersby S., Bubb V.J., Fink G., Harmar A.J., Goodwim G.M., and Smith C.A. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347 (1996) 731-733
30. Parker Jr. C.R., MacDonald P.C., Guzick D.S., Porter J.C., Rosenfeld C.R., and Hauth J.C. Prolactin levels in umbilical cord blood of human infants: relation to gestational age, maternal complications, and neonatal lung function. Am. J. Obstet. Gynecol. 161 (1989) 795-802
31. Robinson D.S., Johnson G.A., Nies A., Corcella J., Cooper T.B., Albright D., and Howard D. Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. J. Clin. Psychopharmacol. 3 (1983) 282-287
32. Sabol S.Z., Hu S., and Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103 (1998) 273-279
33. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60 (1997) 284-295
34. Scheinin M., Karhuvaara S., Ojala-Karlsson P., Kallio A., and Koulu M. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sci. 49 (1991) 75-84
35. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., and Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3 (1998) 508-511
36. Sternbach H. The serotonin syndrome. Am. J. Psychiatry 148 (1991) 705-713
37. Syagailo Y.V., Stober G., Grassle M., Reimer E., Knapp M., Jungkunz G., Okladnova O., Meyer J., and Lesch K.P. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in psychiatric disorders. Am. J. Med. Genet. 105 (2001) 168-171
38. Yu Y.W., Tsai S.J., Chen T.J., Lin C.H., and Hong C.J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol. Psychiatry 7 (2002) 1115-1119
39. Zackrisson A.L., and Lindblom B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur. J. Clin. Pharmacol. 59 (2003) 521-526
40. Zanardi R., Benedetti F., Di Bella D., Catalano M., and Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol. 20 (2000) 105-107